CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...
The early stages of chronic kidney disease (CKD) are usually asymptomatic, with kidney function progressively and ...
A real-world analysis published in JACC Advances concludes that heart failure patients prescribed ivabradine face a significantly higher risk of developing atrial fibrillation (AF) within 180 ...
Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...
The benefits of SGLT2 inhibitors on kidney disease progression in individuals irrespective of diabetes or albuminuria status ...
SGLT2 inhibitors are a welcome addition to GN care, but the field is still grappling with the gap between molecular ...
How to manage an elderly patient with diabetes discharged to primary care following a diagnosis of autonomic neuropathy with ...
Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...
GLORY-2 (NCT06164873) is a Phase 3 clinical study to evaluate the efficacy and safety of mazdutide 9 mg combined with lifestyle intervention versus placebo in Chinese adults with obesity (BMI ≥30 ...
Clinical Trials Arena on MSN
Agomab’s ALK5 inhibitor to advance to Phase IIb in Crohn’s disease
Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...
Letter, Tom Donner, the Director of The Johns Hopkins Diabetes Center, discussed more about the endocrine disorder and his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback